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A 58-year-old man had undergone laparoscopic radical nephrectomy for right renal cell carcinoma.
The histopathological diagnosis was clear cell carcinoma, grade 2＞3, pT1b. Two years and 10 months
postoperatively, computed tomography scans demonstrated an enhanced mass on the right adrenal gland.
As we could not detect other metastatic lesions, it was diagnosed as solitary adrenal metastasis of renal cell
carcinoma. Albeit metastasectomy was planned with curative intent, right hemihepatectomy was also
required for surgical removal because the tumor was adherent to the right lobe of the liver broadly and had
indistinct margins. So we started neoadjuvant therapy with sunitinib. Eight courses of treatment shrunk
the metastatic tumor enough to allow it to be removed completely without partial hepatectomy.
Neoadjuvant therapy with the molecular targeted drugs may provide an effective option for metastasectomy
in renal cell carcinoma regarding increased curability and decreased the risk of an operation.
(Hinyokika Kiyo 60 : 79-82, 2014)











症 例 : 58歳，男性
主 訴 : 肉眼的血尿
家族歴 : 特記事項なし
既往歴 : 高血圧，糖尿病，高脂血症
現病歴 : 2006年 1月，肉眼的血尿を主訴に前医を受
診し右腎腫瘍を指摘され当科紹介受診となった．造影
CT で右腎に径 6 cm 大の早期に造影される腫瘤を認
め (Fig. 1），他に明らかな転移巣を認めなかった． 2
月，腹腔鏡下右腎摘除術を施行した．病理では clear
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cell carcinoma，grade 2＞3，INFα，v ＋，ly −，右腎
細胞癌 pT1bN0M0 の診断であった．手術後，再発の
リスクを考え 3カ月ごとの CT 検査を施行していた
が， 2年10カ月での CT 検査で右副腎に径 2 cm 大の
腫瘍を指摘された．
検査所見 : Hb 14.4 g/dl，CRP 0.6 mg/dl，ESR 23
mm/h，LDH 165 IU/l，Ca 10.1 mg/dl．
画像所見 : 造影 CT では早期相で造影効果があり後
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Fig. 2. Computed tomography shows the right
adrenal tumor with early enhancement,





Fig. 3. Magnetic resonance imaging shows the
adrenal metastasis which has an indistinct
interface with the liver before administration
of sunitinib (A). Gadolinium-enhanced
T1-weighted image shows that the tumor is
close to the right branch of the portal vein
(B : arrow).
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Fig. 4. The clinical response to sunitinib treatment. The size of adrenal metastasis shrunk signiﬁcantly
after 8 courses of sunitinib.
期相で wash out される副腎腫瘍を認めた．腫瘍は肝
と広範に接し，境界が不明瞭であった (Fig. 2）．












泌尿紀要 60巻 2号 2014年80
泌60,02,05-5
Fig. 5. Histological ﬁndings of the right adrenal
tumor. Viable clear cell carcinomas are
focally identiﬁed (A). Necrotizing lesions
are also recognized (B).
ニチニブのさらなる効果が期待できたことや，有害事
































ブを投与したところ，PR が 3人（16％），SD が 7人


































発，stage IV，切除不能淡明細胞癌の ﬁrst line として
スニチニブが推奨されている14)．また，EAU の腎癌
ガイドラインでは転移性腎癌患者の ﬁrst line あるいは
second line としてチロシンキナーゼ阻害剤を考慮すべ
きであるとし，スニチニブは低リスク群と中間リスク
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